VYNE Therapeutics Inc. (NASDAQ: VYNE)
$2.25
+0.1050 ( +4.91% ) 143.7K
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Market Data
Open
$2.25
Previous close
$2.14
Volume
143.7K
Market cap
$32.69M
Day range
$2.05 - $2.37
52 week range
$1.57 - $6.79
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 15, 2023 |
4 | Insider transactions | 1 | Dec 15, 2023 |
4 | Insider transactions | 1 | Dec 15, 2023 |
4 | Insider transactions | 1 | Dec 15, 2023 |
8-k | 8K-related | 16 | Dec 13, 2023 |
4 | Insider transactions | 1 | Dec 04, 2023 |
4 | Insider transactions | 1 | Nov 17, 2023 |
10-q | Quarterly Reports | 51 | Nov 13, 2023 |
3 | Insider transactions | 2 | Nov 13, 2023 |
def | Proxies and info statements | 5 | Nov 13, 2023 |